There are currently 1123 clinical trials in Cincinnati, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cincinnati Children's Hospital Medical Center, University of Cincinnati, University of Cincinnati Medical Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Recruiting
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Investigator Site US025, Cincinnati, Ohio
Conditions: Hidradenitis Suppurativa (HS)
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
Recruiting
The participants of this study will be children, adolescents, and young adults with residual osteosarcoma, which cannot be removed completely through surgery. Participants will have achieved a partial response or stable disease at the end of conventional chemotherapy. Osteosarcoma is cancer of the bone. The cancer cells make immature bone cells, known as osteoid. Osteosarcoma is very rare, but it is the most common type of bone cancer in children and teens. It is most common in teens and young... Read More
Gender:
ALL
Ages:
Between 5 years and 30 years
Trial Updated:
03/28/2025
Locations: Cincinnati Children's Hospital Medical Center - Cancer and Blood Diseases Institute (CBDI), Cincinnati, Ohio
Conditions: Osteosarcoma, Osteosarcoma in Children, Osteosarcoma in Adolescents and Young Adults
A Study of Barzolvolimab in Patients With Prurigo Nodularis
Recruiting
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adults with prurigo nodularis.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: UC Health Physicians Office Dermatology, Cincinnati, Ohio
Conditions: Prurigo Nodularis
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
Recruiting
The purpose of this study is to evaluate effect of povorcitinib on itch and skin lesions in participants with prurigo nodularis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/28/2025
Locations: University of Cincinnati Health Physicians, Cincinnati, Ohio
Conditions: Prurigo Nodularis
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and exposure-response (E-R) of BMS-986435/MYK-224 in participants with symptomatic Heart Failure with Preserved Ejection Fraction (HFpEF).
Gender:
ALL
Ages:
Between 40 years and 90 years
Trial Updated:
03/28/2025
Locations: Local Institution - 0058, Cincinnati, Ohio
Conditions: Heart Failure
Study of SGR-3515 In Participants With Advanced Solid Tumors.
Recruiting
The purpose of this study is to learn about the effects of a new study drug, called SGR-3515 that may be a treatment for advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: University of Cincinnati Medical Center, Cincinnati, Ohio
Conditions: Advanced Solid Tumor
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)
Recruiting
Researchers are looking for other ways to treat people with PAH. In PAH, the blood vessels in the lungs become thick and narrow, which makes it harder for blood to flow to the lungs. The goal of the study is to learn: * What happens to different doses of sotatercept in a person's body over time when it is given using weight-banded doses compared to weight-based doses. There may be differences in how the medicine works with the new dosing method (weight-banded dosing) being studied in this tria... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: University of Cincinnati Medical Center ( Site 1927), Cincinnati, Ohio
Conditions: Pulmonary Arterial Hypertension
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Recruiting
This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Oncology Hematology Care Inc-Eden Park, Cincinnati, Ohio +9 locations
Conditions: Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
ReNEW:Phase 3 Study of Efficacy, Safety & Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects With Dry Age-Related Macular Degeneration (Dry AMD)
Recruiting
The goal of this clinical trial is to evaluate the efficacy, safety and pharmacokinetics of elamipretide in subjects with dry age-related macular degeneration (AMD). The main questions it aims to answer are: what is the rate of change in the macular area of photoreceptor loss in subjects who receive a daily dose of elamipretide compared with those who receive a look-alike substance that contains no active drug, and what is the safety and tolerability of elamipretide daily subcutaneous injections... Read More
Gender:
ALL
Ages:
55 years and above
Trial Updated:
03/28/2025
Locations: MidWest Eye Center, Cincinnati, Ohio
Conditions: Age Related Macular Degeneration (ARMD)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-Small Cell Lung Cancer, ALCHEMIST Trial
Recruiting
This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Good Samaritan Hospital - Cincinnati, Cincinnati, Ohio +4 locations
Conditions: Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Recruiting
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates for first-line treatment. The Phase 3 portion of the study compares the efficacy of adagrasib in combination with pembrolizumab versus pembrolizumab in patients with unresectable, locally advanced or metastatic squamous or nonsquamous NSCLC with KRAS G12C mutati... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Local Institution - 007-893-B, Cincinnati, Ohio +2 locations
Conditions: Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer
Recruiting
This phase III trial compares standard therapy given after surgery (adjuvant) to standard therapy given before and after surgery (perioperative) in treating patients with stage II-IIIB non-small cell lung cancer (NSCLC) that can be removed by surgery (resectable). The usual approach for patients with resectable NSCLC is chemotherapy and/or immunotherapy before surgery, after surgery, or both before and after surgery. This study is being done to find out which approach is better at treating patie... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/28/2025
Locations: Oncology Hematology Care Inc-Kenwood, Cincinnati, Ohio
Conditions: Resectable Lung Non-Small Cell Carcinoma, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8